These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2017069)

  • 21. What's the estimated cost of a national outpatient Rx program?
    Trapnell GR
    Pharm Times; 1980 Jan; 46(1):64-8. PubMed ID: 10245259
    [No Abstract]   [Full Text] [Related]  

  • 22. Drug economics and the elderly: prescriptions for change.
    Lipton HL
    Bus Health; 1988 Mar; 5(5):8-11. PubMed ID: 10312402
    [No Abstract]   [Full Text] [Related]  

  • 23. Economic consequences of the maximum allowable cost program to the entire profession of pharmacy.
    Paul SH
    Med Mark Media; 1979 Aug; 14(8):19-26. PubMed ID: 10243270
    [No Abstract]   [Full Text] [Related]  

  • 24. The cost of drugs: a policy conundrum of global proportions.
    Barry DR; Romig B
    N C Med J; 2003; 64(6):287-8. PubMed ID: 14983620
    [No Abstract]   [Full Text] [Related]  

  • 25. Brand substitution or multiple switches per patient? An analysis of pharmaceutical brand substitution in Australia.
    Kalisch LM; Roughead EE; Gilbert AL
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):620-5. PubMed ID: 18324613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost evaluation of branded and generic drugs.
    Szuba T
    Mater Med Pol; 1987; 19(2):137-42. PubMed ID: 3448420
    [No Abstract]   [Full Text] [Related]  

  • 27. Drug costs can be defended.
    Lee AM
    Med Mark Media; 1982 Mar; 17(3):36, 38, 40 passim. PubMed ID: 10309584
    [No Abstract]   [Full Text] [Related]  

  • 28. Editorial: generic prescriptions: can the consumer benefit?
    Gumbhir AK; Rodowskas CA
    Ann Intern Med; 1975 May; 82(5):711-12. PubMed ID: 1137267
    [No Abstract]   [Full Text] [Related]  

  • 29. Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.
    Morgan SG; Agnew JD; Barer ML
    Health Policy; 2004 Jun; 68(3):299-307. PubMed ID: 15113641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prescription medicines: the costs, the benefits, and the promise.
    Ingram RA
    N C Med J; 2003; 64(6):275-7. PubMed ID: 14983615
    [No Abstract]   [Full Text] [Related]  

  • 31. Annual Albany College of Pharmacy prescription survey.
    DeNuzzo RV
    Med Mark Media; 1979 Apr; 14(4):15-6, 18-20, 22-5 passim. PubMed ID: 10241448
    [No Abstract]   [Full Text] [Related]  

  • 32. [Observations on economizing on drug costs].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1982 May; 126(18):824-9. PubMed ID: 7088209
    [No Abstract]   [Full Text] [Related]  

  • 33. Reimbursement of drug cost-medical assistance program.
    Hosp Formul; 1975 Mar; 10(3):120, 122, 142. PubMed ID: 10297178
    [No Abstract]   [Full Text] [Related]  

  • 34. Generic drug substitution law. Open letter from Attorney General Robert Abrams.
    Abrams R
    N Y State J Med; 1979 Jul; 79(8):1243. PubMed ID: 287925
    [No Abstract]   [Full Text] [Related]  

  • 35. Escalating need for comparative analysis of drugs within a therapeutic class.
    Giaquinta D
    Manag Care Interface; 2003 Oct; 16(10):32-4. PubMed ID: 14606258
    [No Abstract]   [Full Text] [Related]  

  • 36. The high price of mandatory substitution.
    Dickinson J
    Hosp Formul; 1978 Oct; 13(10):811-2. PubMed ID: 10238813
    [No Abstract]   [Full Text] [Related]  

  • 37. Distribution and cost of drugs in a pharmaceutically decentralized health maintenance organization.
    Hardigan WD; Slywka GW; Eng HJ
    Contemp Pharm Pract; 1980; 3(1):23-30. PubMed ID: 10245109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceuticals and medical devices: Medicare Part D. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-23. PubMed ID: 18345558
    [No Abstract]   [Full Text] [Related]  

  • 39. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Forces and direction of drug product selection legislation.
    Stewart JE
    Med Mark Media; 1979 Jun; 14(6):34-6, 38-9. PubMed ID: 10242281
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.